| Apm1 biallelic markers and uses thereof -> Monitor Keywords |
|
|
 
Apm1 biallelic markers and uses thereofRelated Patent Categories: Chemistry: Molecular Biology And Microbiology, Measuring Or Testing Process Involving Enzymes Or Micro-organisms; Composition Or Test Strip Therefore; Processes Of Forming Such Composition Or Test Strip, Involving Nucleic AcidApm1 biallelic markers and uses thereof description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20060166259, Apm1 biallelic markers and uses thereof. Brief Patent Description - Full Patent Description - Patent Application Claims
[0001] This application is a continuation of U.S. patent application Ser. No. 10/376,460, filed Feb. 28, 2003, which is a divisional of U.S. patent application Ser. No. 09/569,852, filed May 10, 2000, now U.S. Pat. No. 6,582,909, which is a continuation-in-part of International Patent Application No. PCT/IB99/01858, filed Nov. 4, 1999 and U.S. Non-Provisional patent application Ser. No. 09/434,848, filed Nov. 4, 1999, now abandoned, both of which claim priority to U.S. Provisional Patent Application Ser. No. 60/119,593, filed Feb. 10, 1999, and U.S. Provisional Patent Application Ser. No. 60/107,113, filed Nov. 4, 1998. All of the above-referenced applications are hereby incorporated by reference herein in their entireties, including any figures, tables, nucleic acid sequences, amino acid sequences, or drawings. FIELD OF THE INVENTION [0002] The invention concerns the genomic and cDNA sequences of the APM1 gene, as well as methods and kits for detecting these polynucleotides. The invention also concerns the regulatory regions, particularly the promoter region of the APM1 gene. The invention comprises biallelic markers of the APM1 gene which can be useful for diagnosis of obesity or disorders related to obesity. BACKGROUND [0003] Obesity is a public health problem that is both serious and widespread. One-third of the population in industrialized countries has an excess weight of at least 20% relative to the ideal weight. The phenomenon continues to worsen, particularly in regions of the globe where economies are modernizing. In the United States, the number of obese people has escalated from 25% at the end of the 70s to 33% at the beginning of the 90s. [0004] Obesity considerably increases the risk of developing cardiovascular and metabolic diseases. It is estimated that if the entire population had an ideal weight, the risk of coronary insufficiency would decrease by 25% and that of cardiac insufficiency and of cerebral vascular accidents by 35%. Coronary insufficiency, atheromatous disease and cardiac insufficiency are at the forefront of the cardiovascular complications induced by obesity. For an excess weight greater than 30%, the incidence of coronary diseases is doubled in subjects less than 50 years old. Studies carried out for other diseases are equally significant. For an excess weight of 20%, the risk of high blood pressure is doubled. For an excess weight of 30%, the risk of developing non-insulin-dependent diabetes is tripled and the risk of hyperlipidemias is multiplied six fold. [0005] The list of diseases having onsets promoted by obesity is long: hyperuricemia (11.4% in obese subjects, compared with 3.4% in the general population), digestive pathologies, abnormalities in hepatic functions, and even certain cancers. [0006] Whether the physiological changes in obesity are characterized by an increase in the number of adipose cells, or by an increase in the quantity of triglycerides stored in each adipose cell, or by both, this excess weight results mainly from an imbalance between the quantities of calories consumed and the quantity of calories used by the body. Some studies on the causes of this imbalance have focused on studying the mechanism of absorption of foods, and therefore the molecules which control food intake and the feeling of satiety. Other studies have characterized the pathways through which the body uses its calories. [0007] The treatments for obesity which have been proposed are of four types. 1) Food restriction is the most frequently used. Obese individuals are advised to change their dietary habits so as to consume fewer calories. This type of treatment is effective in the short-term. However, the recidivation rate is very high. 2) Increased calorie use through physical exercise is also proposed. This treatment is ineffective when applied alone, but it improves, however, weight-loss in subjects on a low-calorie diet. 3) Gastrointestinal surgery, which reduces the absorption of the calories ingested, is effective but has been virtually abandoned because of the side effects which it causes. 4) The medicinal approach uses either the anorexigenic action of molecules involved at the level of the central nervous system, or the effect of molecules which increase energy use by increasing the production of heat. The prototypes of this kind of molecule are the thyroid hormones that uncouple oxidative phosphorylations of the mitochondrial respiratory chain. The side effects and the toxicity of this type of treatment make their use dangerous. An approach that aims to reduce the absorption of dietary lipids by sequestering them in the lumen of the digestive tube is also in place. However, it induces physiological imbalances that are difficult to tolerate: deficiency in the absorption of fat-soluble vitamins, flatulence and steatorrhoea. Whatever the envisaged therapeutic approach, the treatments of obesity are all characterized by an extremely high recidivation rate. [0008] The molecular mechanisms responsible for obesity in man are complex and involve genetic and environmental factors. Because of the low efficiency of the treatments known up until now, it is urgent to define the genetic mechanisms that determine obesity, so as to be able to develop better targeted medicaments. [0009] More than 20 genes have been studied as possible candidates, either because they have been implicated in diseases of which obesity is one of the clinical manifestations, or because they are homologues of genes involved in obesity in animal models. Situated in the 7q31 chromosomal region, the OB gene is one of the most widely studied. Its product, leptin, is involved in the mechanisms of satiety. Leptin is a plasma protein of 16 kDa produced by the adipocytes under the action of various stimuli. Obese mice of the ob/ob type exhibit a deficiency in the leptin gene; this protein is undetectable in the plasma of these animals. The administration of leptin obtained by genetic engineering to ob/ob mice corrects their relative hyperphagia and allows normalization of their weight. This anorexigenic effect of leptin calls into play a receptor of the central nervous system: the ob receptor which belongs to the family of class 1 cytokine receptors. The ob receptor is deficient in obese mice of the db/db strain. The administration of leptin to these mice has no effect on their food intake and does not allow substantial reduction in their weight. The mechanisms by which the ob receptors transmit the signal for satiety are not precisely known. It is possible that neuropeptide Y is involved in this signaling pathway. It is important to specify at this stage that the ob receptors are not the only regulators of appetite. The Melanocortin 4 receptor is also involved since mice made deficient in this receptor are obese (Gura, (1997)). [0010] The discovery of leptin and the characterization of the leptin receptor at the level of the central nervous system opened a new route for the search for medicaments against obesity. This model, however, rapidly proved disappointing. Indeed, with only one exception (Montague et al., (1997)), the genes encoding leptin or its ob receptor have proved to be normal in obese human subjects. Furthermore and paradoxically, the plasma concentrations of leptin, the satiety hormone, are abnormally high in most obese human subjects. [0011] Clearly there remains a need for novel medicaments that are useful for reducing body weight in humans. Such pharmaceutical compositions advantageously would help to control obesity and thereby alleviate many of the cardiovascular consequences associated with this condition. [0012] The human adipocyte-specific APM1 gene encodes a secretory protein of the adipose tissue and is likely to play a role in the pathogenesis of obesity. Knowledge of the APM1 genomic sequence, and particularly of both promoter and splice junction sequences, allows the design of novel diagnostics and therapeutic tools that act on lipid metabolism, and are useful for diagnosing and treating obesity disorders. SUMMARY OF THE INVENTION [0013] The present invention stems from the isolation and characterization of the genomic sequence of APM1 gene including its regulatory regions and of the complete cDNA sequence encoding the APM 1 protein. Oligonucleotide probes and primers hybridizing specifically with a genomic sequence of APM1 are also part of the invention. A further object of the invention consists of recombinant vectors comprising any of the nucleic acid sequences described in the present invention, and in particular of recombinant vectors comprising the promoter region of APM1 or a sequence encoding the APM1 protein, as well as cell hosts comprising said nucleic acid sequences or recombinant vectors. The invention also encompasses methods of screening of molecules which modulate or inhibit the expression of the APM1 gene. The invention is also directed to biallelic markers that are located within the APM1 genomic sequence, these biallelic markers representing useful tools in order to identify a statistically significant association between specific alleles of APM1 gene and one or several disorders related to obesity. Further, the invention relates to the use of these biallelic marker associations to indicate people at risk for diseases, including obesity-related diseases, as well as to identify people who would be candidates or non-candidates for a drug treatment, or a clinical trial. BRIEF DESCRIPTION OF THE FIGURES [0014] FIG. 1 shows a map of the genomic organization of human Apm1 (Adipose Most Abundant Gene Transcript 1) and the location of the biallelic markers identified in the application. [0015] FIGS. 2A, 2B, and 2C are a graphical representation of the effect of Apm1 polymorphisms on plasma lipid values in obese adolescent girls. The mean and 99.99% confidence interval are indicated as a solid and dotted line, respectively. [0016] FIGS. 3A and 3B are a graphical representation of the effect of APM1 polymorphism on leptin/BMI relationship in obese adolescent girls. [0017] FIGS. 4A and 4B are a graphical representation of the effect of APM1 polymorphism on FFA in obese adolescents girls. [0018] FIGS. 5A and 5B are a graphical representation of the effect of APM1 polymorphism on respiratory quotient in obese adolescents. [0019] FIG. 6 is a graphical representation of the effect of APM1 on leptin/BMI ratio in obese adolescents girls. [0020] FIG. 7 is a graphical representation of the effect of APM1 polymorphism on glucose tolerance in obese adolescent girls. Continue reading about Apm1 biallelic markers and uses thereof... Full patent description for Apm1 biallelic markers and uses thereof Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Apm1 biallelic markers and uses thereof patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Apm1 biallelic markers and uses thereof or other areas of interest. ### Previous Patent Application: Allosteric enzyme coupled immunoassay (aecia) Next Patent Application: Apparatus and system having dry control gene silencing compositions Industry Class: Chemistry: molecular biology and microbiology ### FreshPatents.com Support Thank you for viewing the Apm1 biallelic markers and uses thereof patent info. IP-related news and info Results in 0.53739 seconds Other interesting Feshpatents.com categories: Electronics: Semiconductor , Audio , Illumination , Connectors , Crypto , 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
